TREATING PATHOLOGICAL CONDITIONS BY DIRECT AND INDIRECT TARGETING OF SIRPALPHA - CD47 INTERACTIONThe present invention relates to active agents or compounds as well as pharmaceutical compositions comprising said compounds, which are capable of reducing or inhibiting or blocking the enzymatic activity of ...
本发明公开了一种利用HTRF一步法筛选CD47/SIRP alpha阻断剂的方法,属于阻断剂筛选方法领域.该筛选方法包括如下步骤:配置已构建好的带有不同标签的CD47及SIRP alpha蛋白,作为待筛选样品;在微孔板中依次加入待筛选样品CD47及SIRP alpha蛋白;室温孵育,用酶标仪读数检测荧光,665nm/620nm的比值为原始数据.本发明实现了...
本发明公开了一种利用HTRF一步法筛选CD47/SIRP alpha阻断剂的方法,属于阻断剂筛选方法领域。该筛选方法包括如下步骤:配置已构建好的带有不同标签的CD47及SIRP alpha蛋白,作为待筛选样品;在微孔板中依次加入待筛选样品CD47及SIRP alpha蛋白;室温孵育,用酶标仪读数检测荧光,665nm/6... 查看全部>> 免费获取 收...
kappa/lambda bodies illustrates the power of the dual-targeting approach: A favorable safety profile and pharmacokinetics could be achieved in parallel to potent inhibition of the CD47-SIRP alpha interaction and effective cancer cell killing... K Masternak,Z Johnson,V Buatois,... - 《Cancer Immuno...
CD47 [Biotinylated] : SIRP alpha Inhibitor Screening ELISA Kit 中文名: 中文别名: CBNumber: CB215553531 分子式: 分子量: 0 MOL File: Mol file 化学性质安全信息用途供应商1 CD47 [Biotinylated] : SIRP alpha Inhibitor Screening ELISA Kit化学性质 ...
Interaction between target cell CD47 and the inhibitory macrophage receptor signal regulatory protein alpha (SIRPalpha) counteracts macrophage phagocytosis... M Olsson,P Bruhns,WA Frazier,... - 《Blood》 被引量: 169发表: 2005年 加载更多来源
MODULATION OF SIRPALPHA - CD47 INTERACTION FOR INCREASING HUMAN HEMATOPOIETIC STEM CELL ENGRAFTMENT AND COMPOUNDS THEREFORThe invention relates to modulating the SIRP± - CD47 interaction in order to increase hematopoietic stem cell engraftment and compounds therefor. In some embodiments, there is ...
A method for treating a blood cancer, including a process for adjusting the interaction between human SIRP. Alpha. And human CD47. Preferably, the interaction between human CIRP 伪 and human CD47 is regulated by administering therapeutic effective amounts of polypeptides capable of binding to the ...
Attenuation of phagocytosis of xenogeneic cells by manipulating CD47. Signal regulatory protein alpha (SIRPalpha) is a critical immune inhibitory receptor on macrophages, and its interaction with CD47, a ligand for SIRPalpha,... H Wang,J Verhalen,ML Madariaga,... - 《Blood》 被引量: 150发表...
CD47+ disease cells, such as CD47+ cancer cells, are treated with an agent that blocks signalling via the SIRPalpha /CD47 axis. The agent is a human SIRPalpha fusion protein that displays negligible CD47 agonism and negligible red blood cell binding. The fusion protein comprises an IgV domain...